Sumithra J. Mandrekar, Ph.D., is the lead faculty statistician for lung cancer research at Mayo Clinic and the Alliance for Clinical Trials in Oncology. She is also the lead faculty statistician for the Cancer Prevention Network, and the Leukemia Committee within the Alliance for Clinical Trials in Oncology. Within these groups, she is involved in multiple clinical trials and research grants.
Dr. Mandrekar's research interests are in the areas of design and analysis of clinical trials in cancer, and general clinical trial methodology.
- Dose-finding trial designs
- Designs for initial and definitive biomarker validation
- Tumor measurement-based clinical trial endpoints
- Pooled analyses
Significance to patient care
The translation of clinical research to practice in the field of oncology has been slow, despite a growing understanding of the genetic and molecular basis of this disease.
While a myriad of factors impact this slow pace of progress, issues relating to clinical trial design play a significant role, including patient selection, choice of endpoints, choice of control arm and assay-related issues.
An optimal design can help improve the success rate of clinical drug development, bring down trial costs in terms of patients and resources, and prevent patients from being exposed to toxic treatments that may not benefit them.
- Co-director, Biostatistics Shared Resource, Mayo Clinic Cancer Center, 2012-present
- Biostatistics editor, Journal of Thoracic Oncology, 2011-present
- Member, Clinical Imaging Steering Committee, National Cancer Institute, 2011-present
- Adjunct professor of biostatistics, School of Public Health, University of Minnesota, 2008-present
- Member, Thoracic Malignancy Steering Committee, National Cancer Institute, 2008-present